within Pharmacolibrary.Drugs.ATC.N;

model N02BG02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02BG02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rimazolium is a quaternary ammonium derivative with analgesic properties, classified as an opioid analgesic. It was formerly used as an adjunct in anesthesia due to its analgesic and sedative effects, but it is not approved or used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies specifically detailing rimazolium parameters in humans or animals have been found. The following are estimated parameters assuming a typical opioid pharmacokinetic one-compartment model with intravenous administration in healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02BG02;
